You are viewing the site in preview mode

Skip to main content


Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning

Fig. 5

Vaccination, bolus IL-2 and infusion of tumor-reactive lymphocytes are required to potentate ACT tumor treatment in irradiated mice given LPS. a LPS augmented the antitumor activity of CD8+ T cells in irradiated mice given the tripartite treatment. b Removal of pmel-1 T cells; c fowlpox hgp100 vaccine or d bolus IL-2 impaired the enhanced antitumor response mediated in irradiated mice given a tripartite therapy and LPS. One day after TBI, mice received an ACT treatment comprised of the adoptive transfer of 5e5 cultured pmel-1 T cells, fowlpox hgp100 vaccination and hIL-2 or were left untreated. The next day, mice received 2 μg of LPS or left untreated. Data shown (mean ± SEM, 5–10 mice per group) are representative of 2 independent experiments. 5Gy (white triangle) vs. 5Gy PFI (white circle, *P < .05), 5Gy FI+ LPS (grey triangle, NS), 5Gy PI + LPS (grey square, *P < .05) or 5Gy PF + LPS (grey diamond, *P < .05), ANOVA. 5Gy PFI + LPS (black circle) vs. 5Gy PFI (white circle, *P < .05), 5Gy FI + LPS (grey triangle, ***P < .001), 5Gy PI + LPS (grey square, **P < .01) or 5Gy PF + LPS (grey diamond, *P < .05), ANOVA

Back to article page